8-K: Jasper Therapeutics CFO Departs, Interim Team Appointed

Jasper Therapeutics announced the resignation of its CFO, Herb Cross, effective October 9, 2026, with interim appointments made to fill the key financial roles.

Summary

• Jasper Therapeutics, Inc. (JSPR) announced that its Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, and Corporate Secretary, Herb Cross, has resigned, effective October 9, 2026.
• The company has appointed Jeet Mahal (President and CEO) as interim Principal Financial Officer, Rick Ruiz (VP, Finance) as interim Principal Accounting Officer, and Matthew Ros (Chief Operating Officer) as interim Corporate Secretary, effective upon Mr. Cross's resignation.
• Rick Ruiz, age 62, has been with the company since 2024 and has over 25 years of experience in finance, accounting, FP&A, and SEC reporting. He will continue to receive his base salary of $364,000 and remain eligible for equity awards.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the unexpected departure of a key financial officer, although interim appointments aim to mitigate immediate disruption.

Positives

• Interim appointments have been made promptly to ensure continuity in financial leadership.
• Rick Ruiz, the interim Principal Accounting Officer, has extensive experience (over 25 years) in finance and accounting, including SEC reporting.
• Rick Ruiz's compensation remains unchanged, indicating no immediate financial burden from his interim role.

Negatives

• The unexpected resignation of the CFO, Principal Financial Officer, Principal Accounting Officer, and Corporate Secretary creates uncertainty.
• The departure of Herb Cross, who held multiple critical financial roles, could signal underlying issues or a lack of confidence in the company's direction.

Risks

• Potential disruption to financial operations and reporting due to the transition in key financial leadership.
• Difficulty in attracting a permanent, qualified CFO in a timely manner, especially if the company faces significant challenges.
• Investor confidence may be negatively impacted by the sudden departure of a senior executive.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. The focus is on the immediate executive transition.

Management Comments

• Herb Cross resigned 'in order to pursue other professional endeavors.'

Industry Context

StockSavvy.ai notes that executive turnover, particularly in CFO roles, can be a sensitive indicator for investors. In the biotechnology sector, where funding and clinical trial progress are paramount, stable financial leadership is crucial for maintaining investor confidence and navigating complex financial landscapes.

Comparison to Industry Standards

• In the biotechnology sector, companies often face high executive turnover due to the inherent risks and long development cycles. However, the departure of a CFO, especially one holding multiple key financial titles, is generally viewed negatively unless a clear succession plan is in place.
• Competitors like Moderna and BioNTech have maintained relatively stable executive teams during periods of significant growth and product development, which is often seen as a positive sign of operational strength.

Management Changes

Stakeholder Impact

• Shareholders: Potential negative impact on stock price due to uncertainty surrounding executive leadership and potential operational disruptions.
• Employees: May experience uncertainty regarding the company's future direction and financial stability.
• Creditors/Suppliers: May face increased scrutiny of the company's financial health and ability to meet obligations.

Next Steps

• The company will need to appoint a permanent Chief Financial Officer and potentially other officers to fill the roles vacated by Herb Cross.
• The interim officers will manage the company's financial operations until permanent appointments are made.

Key Dates

Recommendation

The departure of the CFO creates immediate uncertainty, warranting a 'hold' recommendation until a permanent replacement is appointed and the company demonstrates stability in its financial leadership and operations. The interim appointments provide some comfort, but the overall situation warrants caution.

Keywords

CFO resignation, Interim CFO, Financial Officer Appointment, Corporate Secretary, Jasper Therapeutics, Executive Transition, SEC Reporting